The Role of VEGF-C and VEGF-D in Coronary Artery Disease: From Molecular Pathophysiology to Therapeutic Lymphangiogenesis
Abstract
Traditional therapeutic strategies for coronary artery disease (CAD) primarily focus on arterial perfusion, largely overlooking the critical role of the cardiac lymphatic system in maintaining myocardial fluid, lipid, and immune homeostasis. The vascular endothelial growth factor C (VEGF-C) and VEGF-D/VEGF receptor-3 (VEGFR3) signaling axes are the primary drivers of lymphangiogenesis. However, recent clinical and mechanistic insights suggest that these two homologous ligands exert highly distinct and divergent pathophysiological roles under ischemic stress. This review synthesizes the current clinical, epidemiological, and preclinical evidence evaluating the distinct temporal and spatial dynamics of the VEGF-C/D axis. Large-scale clinical cohorts have revealed a striking prognostic divergence: while elevated circulating VEGF-D levels independently predict incident heart failure, atrial fibrillation, and mortality, low serum VEGF-C levels independently predict mortality. Mechanistically, adventitial lymphatics actively govern scavenger receptor class B type I (SR-BI)-dependent reverse cholesterol transport and macrophage trafficking. Preclinical large animal validation and phase 1/2 clinical trials (such as KAT301 and ReGenHeart) have demonstrated that timely, localized pro-lymphangiogenic interventions-leveraging modified mRNA, lipid nanoparticles, or sequential growth factor delivery kinetics-effectively resolve myocardial edema, suppress adverse remodeling, and improve the myocardial perfusion reserve. In conclusion, VEGF-C and VEGF-D represent a complex molecular dualism in CAD. Transitioning from non-specific growth factor overproduction to cell-specific, sequentially timed lymphatic therapeutics is a new frontier in halting the progression of adverse ventricular remodeling and chronic heart failure.
Related
- Epicardial Adipose Tissue as a Dynamic Modulator of Coronary Artery Disease Phenotypes: Pathophysiology and Therapeutic Implications
- Editorial: Chronic large-vessel occlusion in cerebrovascular disease: pathophysiology, diagnosis, and therapeutic advances
- Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome
- Thyroid Eye Disease in the Teprotumumab Era: Pathophysiology, Clinical Activity Assessment, and an Updated Therapeutic Landscape
- Stiff-Person Syndrome: A Comprehensive Review of a Rare Disease with Emphasis on Pathophysiology, Clinical Features, Diagnostic Challenges and Therapeutic Advances.
BibTeX
@article{wada2026role,
title = {{The Role of VEGF-C and VEGF-D in Coronary Artery Disease: From Molecular Pathophysiology to Therapeutic Lymphangiogenesis}},
author = {Hiromichi Wada and Kazuhiko Kotani and Moritake Iguchi and Koji Hasegawa},
journal = {Journal of Atherosclerosis and Thrombosis},
year = {2026},
month = aug,
doi = {10.5551/jat.rv22058},
url = {https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_RV22058/_article},
note = {CC BY-NC-SA},
}
RIS
TY - JOUR
TI - The Role of VEGF-C and VEGF-D in Coronary Artery Disease: From Molecular Pathophysiology to Therapeutic Lymphangiogenesis
AU - Hiromichi Wada
AU - Kazuhiko Kotani
AU - Moritake Iguchi
AU - Koji Hasegawa
PY - 2026
DA - 2026/08/19
JO - Journal of Atherosclerosis and Thrombosis
DO - 10.5551/jat.rv22058
UR - https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_RV22058/_article
AB - Traditional therapeutic strategies for coronary artery disease (CAD) primarily focus on arterial perfusion, largely overlooking the critical role of the cardiac lymphatic system in maintaining myocardial fluid, lipid, and immune homeostasis. The vascular endothelial growth factor C (VEGF-C) and VEGF-D/VEGF receptor-3 (VEGFR3) signaling axes are the primary drivers of lymphangiogenesis. However, recent clinical and mechanistic insights suggest that these two homologous ligands exert highly distinct and divergent pathophysiological roles under ischemic stress. This review synthesizes the current clinical, epidemiological, and preclinical evidence evaluating the distinct temporal and spatial dynamics of the VEGF-C/D axis. Large-scale clinical cohorts have revealed a striking prognostic divergence: while elevated circulating VEGF-D levels independently predict incident heart failure, atrial fibrillation, and mortality, low serum VEGF-C levels independently predict mortality. Mechanistically, adventitial lymphatics actively govern scavenger receptor class B type I (SR-BI)-dependent reverse cholesterol transport and macrophage trafficking. Preclinical large animal validation and phase 1/2 clinical trials (such as KAT301 and ReGenHeart) have demonstrated that timely, localized pro-lymphangiogenic interventions-leveraging modified mRNA, lipid nanoparticles, or sequential growth factor delivery kinetics-effectively resolve myocardial edema, suppress adverse remodeling, and improve the myocardial perfusion reserve. In conclusion, VEGF-C and VEGF-D represent a complex molecular dualism in CAD. Transitioning from non-specific growth factor overproduction to cell-specific, sequentially timed lymphatic therapeutics is a new frontier in halting the progression of adverse ventricular remodeling and chronic heart failure.
SN - 1880-3873
SN - 1340-3478
ER -